Long before substance use resumes, a person may already be moving through a sequence of emotional, cognitive and behavioural changes: withdrawing from support, experiencing growing stress or becoming increasingly preoccupied with craving. By the time substance use actually occurs, the relapse process may already be well underway. So what actually helps? Could neurofeedback offer a new way to strengthen self-regulation? This article explores evidence-based approaches to relapse prevention in addiction.
Relapse prevention in addiction: what actually helps?
Explore effective strategies for addiction relapse prevention, understand the brain mechanisms involved and learn more about Neuromind's innovative solution.
Overview.
Key takeaways.
Relapse is a recognised feature of addiction, a chronic condition influenced by biological, psychological and environmental factors.
Craving, stress reactivity, impaired executive control and cue-induced responses can all contribute to relapse vulnerability.
Alterations in the Default Mode Network have been associated with self-referential craving, rumination and difficulties disengaging from internally driven urges.
Evidence-based relapse prevention methods include cognitive behavioural therapy, mindfulness-based interventions, medication, neurofeedback and ongoing support.
Neuromind uses EEG neurofeedback and immersive virtual reality to target neurophysiological mechanisms associated with craving and relapse.
01
Why is relapse common in addiction?
Relapse is part of a chronic condition.
Addiction is a chronic medical condition in which periods of recovery can be followed by renewed substance use [1]. Statistics indicate that 40% to 60% of people with addiction will experience a relapse [2]. Therefore, relapse should not automatically be interpreted as a failure of treatment or a lack of motivation.
The relapse prevention model described by the National Center for Biotechnology Information illustrates how this can unfold [3]:
Emotional relapse can involve isolation, poor self-care, stress or disengagement from recovery supports.
Mental relapse may then encompass craving, memories of previous substance use, bargaining or actively seeking opportunities to use.
Physical relapse describes the return to substance use.
However, recognising addiction as chronic doesn't mean accepting it as inevitable. A return to substance use can have serious consequences, including overdose and other health risks, particularly after a period of abstinence when tolerance may have changed [1].
The clinical objective is twofold: reduce the likelihood of relapse and recognise vulnerability early enough to intervene.
The neurobiology of relapse: craving, stress and brain networks.
Addiction involves interacting neural systems involved in reward, motivation, stress, salience and executive control [4]. Repeated substance exposure can alter these circuits, making previously neutral cues increasingly significant. A particular place, person, smell, image or emotional state can become a conditioned cue capable of eliciting craving.
A systematic review and meta-analysis of 18 studies found significant associations between drug cues, craving and subsequent drug use or relapse, supporting cue reactivity as an important mechanism in substance use disorders [5].
Stress adds another layer. Research has identified biological stress responses as predictors of relapse vulnerability, suggesting that stress regulation is an important part of recovery [6].
At the same time, addiction can affect prefrontal systems involved in executive control. These systems contribute to inhibitory control, decision-making, salience attribution and the ability to maintain behaviour aligned with longer-term goals [7].
Together, these mechanisms create a difficult cycle: a cue can trigger craving, stress can amplify it, and impaired control can make it harder to disengage.
02
The role of the Default Mode Network in addiction relapse
A self-referential brain state.
The Default Mode Network (DMN) is a large-scale brain network involved in self-referential processing, internally directed attention and mind-wandering [8]. In addiction, alterations in DMN function and connectivity have been associated with craving and relapse vulnerability [9].
DMN dysfunction in addiction has been linked to four related problems:
persistent self-referential craving and rumination;
difficulty disengaging from internally driven urges;
impaired coordination between the DMN and executive control networks;
increased vulnerability to cue-triggered relapse under stress.
Research has also found altered resting-state connectivity between the DMN and networks involved in salience and executive control [10]. These interactions are important for shifting attention and regulating behaviour [11].
A person experiencing craving is not necessarily unable to regulate it. The difficulty rather lies in the capacity to shift away from an internally driven state and re-engage regulatory processes.
03
What are the most effective relapse prevention strategies?
A tailored approach.
Addiction treatment is most effective when it's tailored to the substance involved, the person's clinical history, co-occurring conditions, level of risk and recovery goals. Several approaches are already used in evidence-based relapse prevention.
Cognitive behavioural therapies (CBT).
Cognitive behavioural approaches help people recognise the situations, thoughts, emotions and behaviours that can increase the likelihood of substance use. The strategies focus on identifying high-risk situations before they become overwhelming and build alternative scenarios that support recovery.
Someone might rehearse how to refuse a drink at a social event, plan whom to call during a craving or choose an alternative activity when stress begins to build. CBT-based relapse prevention strengthens self-efficacy: the confidence that difficult situations can be handled without returning to substance use [12].
Mindfulness-based relapse prevention (MBRP).
What happens when the trigger cannot simply be avoided? Mindfulness-based relapse prevention teaches people to observe thoughts, emotions and bodily sensations without automatically reacting to them. A craving can be intense without becoming an instruction to act.
MBRP builds on traditional relapse prevention by incorporating mindfulness-based practices to increase awareness of cravings and uncomfortable internal experiences without judging them or automatically responding to them.
A 2022 meta-analysis of eight randomised controlled trials found reductions in addictive behaviours and small-to-moderate reductions in craving [13]. Regarding mindfulness and the DMN activity, research suggests that meditation experience influences the neural systems involved in self-referential processing [14].
A randomised clinical trial comparing MBRP, standard relapse prevention and treatment as usual found that both MBRP and standard RP reduced the risk of drug use. At 12 months, MBRP was also associated with fewer days of substance use and heavy drinking [15].
Medication-assisted treatment.
For some substance use disorders, pharmacological treatment is an important part of relapse prevention. Medication can address physiological and neurobiological components of addiction that behavioural interventions alone may not fully target.
The appropriate treatment depends on the substance and the individual's clinical situation. For example, medications such as methadone and buprenorphine are established treatments for opioid use disorder, while medications such as naltrexone and acamprosate can be used for alcohol use disorder [3].
Neurofeedback.
Instead of only asking what a person thinks or feels during a craving, neurofeedback makes brain activity part of the training itself. EEG neurofeedback measures electrical brain activity and provides real-time feedback, allowing individuals to learn to regulate targeted neural states over repeated sessions [16]. This approach offers a direct way of working with mechanisms such as self-regulation, arousal and attentional control.
A 2025 systematic review examined EEG, fMRI and fNIRS neurofeedback interventions across substance use disorders and behavioural addictions and identified reduced craving as a recurring outcome [17].
More recently, a systematic review and meta-analysis of 17 randomised controlled trials involving 662 participants found that EEG neurofeedback significantly reduced addiction-related symptoms [18].
Social support and long-term follow-up.
Recovery also takes place in everyday life: at home, at work, with friends, during periods of stress and in the situations where previous substance use occurred.
The Centre for Addiction and Mental Health recommends helping people reconnect with family, rebuild supportive social networks and develop concrete plans for dealing with strong cravings.
The Recovery Research Institute similarly emphasises the importance of identifying lifestyle factors that increase exposure to triggers such as sleep, eating habits and social environments.
Long-term follow-up makes it possible to respond when risk changes rather than waiting for a full relapse to occur.
04
How Neuromind combines neurofeedback and virtual reality for relapse prevention
A closed-loop platform.
What if relapse prevention could go one step further? Neuromind brings wearable EEG, artificial intelligence and immersive virtual reality together in a closed-loop system designed to address the neurophysiological mechanisms underlying addiction.
Our platform continuously monitors EEG-derived biomarkers related to arousal, attention and emotional state. Its machine-learning system analyses changes in neural activity associated with DMN engagement and uses this information to adapt the virtual environment in real time. Patients train their ability to shift away from craving-prone brain states and towards more regulatory, task-oriented states.
Neuromind is designed as a precision augmentation layer, not a replacement for pharmacological or psychotherapeutic treatment. Our solution can complement inpatient rehabilitation, outpatient addiction programmes, MBRP protocols, multimodal treatment and clinical research.
If you are developing new approaches to addiction treatment or relapse prevention, we would be delighted to explore a clinical or research collaboration.
Stress, substance-related cues, negative emotional states and craving are among the most important relapse drivers. Identifying personal triggers is therefore one of the first steps towards effective relapse prevention.
References
[1] McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000 Oct 4;284(13):1689-95. doi: 10.1001/jama.284.13.1689. PMID: 11015800.
[2] Kitzinger RH Jr, Gardner JA, Moran M, Celkos C, Fasano N, Linares E, Muthee J, Royzner G. Habits and Routines of Adults in Early Recovery From Substance Use Disorder: Clinical and Research Implications From a Mixed Methodology Exploratory Study. Subst Abuse. 2023 Feb 11;17:11782218231153843. doi: 10.1177/11782218231153843. PMID: 36798446; PMCID: PMC9926005.
[3] Guenzel N, McChargue D. Addiction Relapse Prevention. [Updated 2023 Jul 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-.
[4] Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016 Aug;3(8):760-773. doi: 10.1016/S2215-0366(16)00104-8. PMID: 27475769; PMCID: PMC6135092.
[5] Vafaie N, Kober H. Association of Drug Cues and Craving With Drug Use and Relapse: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022;79(7):641–650. doi:10.1001/jamapsychiatry.2022.1240
[6] Sinha R. New findings on biological factors predicting addiction relapse vulnerability. Curr Psychiatry Rep. 2011 Oct;13(5):398-405. doi: 10.1007/s11920-011-0224-0. PMID: 21792580; PMCID: PMC3674771.
[7] Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci. 2011 Oct 20;12(11):652-69. doi: 10.1038/nrn3119. PMID: 22011681; PMCID: PMC3462342.
[8] Raichle ME, Snyder AZ. A default mode of brain function: a brief history of an evolving idea. Neuroimage. 2007 Oct 1;37(4):1083-90; discussion 1097-9. doi: 10.1016/j.neuroimage.2007.02.041. Epub 2007 Mar 6. PMID: 17719799.
[9] Zhang R, Volkow ND. Brain default-mode network dysfunction in addiction. Neuroimage. 2019 Oct 15;200:313-331. doi: 10.1016/j.neuroimage.2019.06.036. Epub 2019 Jun 21. PMID: 31229660.
[10] Sutherland MT, McHugh MJ, Pariyadath V, Stein EA. Resting state functional connectivity in addiction: Lessons learned and a road ahead. Neuroimage. 2012 Oct 1;62(4):2281-95. doi: 10.1016/j.neuroimage.2012.01.117. Epub 2012 Feb 1. PMID: 22326834; PMCID: PMC3401637.
[11] Seeley WW, Menon V, Schatzberg AF, Keller J, Glover GH, Kenna H, Reiss AL, Greicius MD. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci. 2007 Feb 28;27(9):2349-56. doi: 10.1523/JNEUROSCI.5587-06.2007. PMID: 17329432; PMCID: PMC2680293.
[12] National Institute on Drug Abuse (NIDA). 2020, July 6. Treatment and Recovery. Retrieved from nida.nih.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery on 2026, August 16
[13] Parisi A, Roberts RL, Hanley AW, Garland EL. Mindfulness-Oriented Recovery Enhancement for Addictive Behavior, Psychiatric Distress, and Chronic Pain: A Multilevel Meta-Analysis of Randomized Controlled Trials. Mindfulness (N Y). 2022;13(10):2396-2412. doi: 10.1007/s12671-022-01964-x. Epub 2022 Sep 15. PMID: 36124231; PMCID: PMC9476401.
[14] Brewer JA, Worhunsky PD, Gray JR, Tang YY, Weber J, Kober H. Meditation experience is associated with differences in default mode network activity and connectivity. Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20254-9. doi: 10.1073/pnas.1112029108. Epub 2011 Nov 23. PMID: 22114193; PMCID: PMC3250176.
[15] Bowen S, Witkiewitz K, Clifasefi SL, Grow J, Chawla N, Hsu SH, Carroll HA, Harrop E, Collins SE, Lustyk MK, Larimer ME. Relative efficacy of mindfulness-based relapse prevention, standard relapse prevention, and treatment as usual for substance use disorders: a randomized clinical trial. JAMA Psychiatry. 2014 May;71(5):547-56. doi: 10.1001/jamapsychiatry.2013.4546. PMID: 24647726; PMCID: PMC4489711.
[16] Sitaram R, Ros T, Stoeckel L, Haller S, Scharnowski F, Lewis-Peacock J, Weiskopf N, Blefari ML, Rana M, Oblak E, Birbaumer N, Sulzer J. Closed-loop brain training: the science of neurofeedback. Nat Rev Neurosci. 2017 Feb;18(2):86-100. doi: 10.1038/nrn.2016.164. Epub 2016 Dec 22. Erratum in: Nat Rev Neurosci. 2019 May;20(5):314. doi: 10.1038/s41583-019-0161-1. PMID: 28003656.
[17] Fathi M, Ebrahimi MN, Banazadeh M, Shirvani A, Kamalahmadi N, Amiri H, Talaei A. A systematic review on the role of EEG and fMRI-Neurofeedback training in the treatment of substance use disorders and behavioral addiction. Psychiatry Res. 2025 Jul;349:116474. doi: 10.1016/j.psychres.2025.116474. Epub 2025 Apr 20. PMID: 40300301.
[18] Wan H, Chen B, Li X, Bu J. Effect of EEG neurofeedback therapy on addiction disorders: A systematic review and meta-analysis. Addiction. 2026 Feb;121(2):225-238. doi: 10.1111/add.70164. Epub 2025 Aug 12. PMID: 40798852.
Contact. If you would like further information or a demonstration of our solution, please contact us using the following link